Evidence map›Paper›PMID 32152813›Full record

Trial reportMusculoskeletal surgery2021

Hidden blood loss in direct anterior total hip arthroplasty: a prospective, double blind, randomized controlled trial on topical versus intravenous tranexamic acid.

G F Vles, K Corten, R Driesen, C van Elst, S G Ghijselings

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Musculoskeletal surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01940692 (TOPICAL AND INTRAVENOUS ADMINISTRATION OF TRANEXAMIC ACID ARE EQUALLY EFFECTIVE IN DIRECT ANTERIOR TOTAL HIP ARTHROPLASTY - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL), which is not on this map. Cited by 16 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01940692 phase2completednot on this map

Topical and intravenous administration of tranexamic acid are equally effective in direct anterior total hip arthroplasty - a prospective randomized controlled trial

TypeinterventionalSponsorZiekenhuis Oost-LimburgRan2014 to 2015Enrolled120ConditionsOsteoarthrosisArms1.5g intravenous Exacyl, 3.0g intra-articular Exacyl
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Is tranexamic acid safe for the hip joint?Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

G F VlesDepartment of Orthopaedic Surgery, University Hospitals Leuven - Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium. gfvles@gmail.com.
K CortenDepartment of Orthopaedic Surgery, ZOL Genk, Genk, Belgium.
R DriesenDepartment of Orthopaedic Surgery, ZOL Genk, Genk, Belgium.
C van ElstDepartment of Orthopaedic Surgery, AZ Nikolaas, Sint-Niklaas, Belgium.
S G GhijselingsDepartment of Orthopaedic Surgery, University Hospitals Leuven - Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite a plethora of literature reporting on the use of tranexamic acid (TXA) in total hip arthroplasty (THA), little is available on its effect on post-operative hidden blood loss and even less on its use in the direct anterior approach (DAA), which is gaining popularity. MATERIALS AND

methodsThis study was designed as a prospective, double blind, single centre, randomized controlled trial. Sixty patients were allocated to intravenous administration of 1.5 g of TXA just before wound closure while 60 patients were allocated to topical application of 3.0 g of TXA via a subfascial drain at the end of the procedure. Post-operative blood loss was (1) calculated via a well-established formula based on pre- and post-operative Hb levels, patients characteristics and intra-operative blood loss and (2) measured via the amount that collected in the subfascial drain over time.

resultsNo statistical significant difference in post-operative blood loss was found, neither when the formula was used (0.55 L [topical] vs 0.67 L [IV]; p = .140) nor when looking at the drain output (0.25 L [topical] vs 0.29 L [IV]; p = .108). No significant difference in secondary outcome measures, such as transfusion of units of packed red blood cells, length of hospital stay or the occurrence of venous thromboembolisms, could be found either.

conclusionsThis study provides detailed insights into the intra- and post-operative blood loss in DAA THA and shows that topical and IV TXA have similar effects on hidden blood loss. Clinical Trial Number: NCT01940692. LEVEL OF EVIDENCE I: Level I-Randomized Controlled Trial.

Indexed as

Antifibrinolytic AgentsArthroplasty, Replacement, HipTranexamic AcidAdministration, IntravenousAdministration, TopicalBlood Loss, SurgicalHumansProspective StudiesAntifibrinolytic AgentsTranexamic Acid

Identifiers

PMID32152813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.